Biomarkers of Alzheimer's disease

[1]  Anders Wallin,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[2]  Owen Carmichael,et al.  TRAJECTORIES OF BRAIN LOSS IN AGING AND THE DEVELOPMENT OF COGNITIVE IMPAIRMENT , 2009, Neurology.

[3]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[4]  K. Blennow,et al.  The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. , 2008, Clinical chemistry.

[5]  P. Deyn,et al.  Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia , 2008, Neurobiology of Aging.

[6]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[7]  D. Geschwind,et al.  Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.

[8]  J. Becker,et al.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.

[9]  Bradford C. Dickerson,et al.  Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: Insights from functional MRI studies , 2008, Neuropsychologia.

[10]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[11]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[12]  S. Younkin,et al.  Plasma amyloid β protein is elevated in late-onset Alzheimer disease families , 2008, Neurology.

[13]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[14]  G. Frisoni,et al.  MRI of hippocampus and entorhinal cortex in mild cognitive impairment: A follow-up study , 2008, Neurobiology of Aging.

[15]  Markus Schwaiger,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.

[16]  Maija Pihlajamäki,et al.  Increased fMRI responses during encoding in mild cognitive impairment , 2007, Neurobiology of Aging.

[17]  M. J. Leon,et al.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD , 2007, Journal of Neurology.

[18]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[19]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[20]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[21]  K. Blennow,et al.  Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies , 2007, Neurology.

[22]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[23]  J. Growdon,et al.  Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease , 2007, Neurodegenerative Diseases.

[24]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[25]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[26]  Animesh Nandi,et al.  Serum biomarkers for Alzheimer's disease: proteomic discovery. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  David Eidelberg,et al.  Imaging markers of mild cognitive impairment: Multivariate analysis of CBF SPECT , 2007, Neurobiology of Aging.

[28]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[29]  B. Miller,et al.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.

[30]  Kazuhiko Yanai,et al.  2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.

[31]  Matthew P. Frosch,et al.  Plasma A&bgr; Levels Do Not Reflect Brain A&bgr; Levels , 2007 .

[32]  Hilkka Soininen,et al.  CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI , 2007, Neurobiology of Aging.

[33]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[34]  J. Hiltunen,et al.  Brain function during multi-trial learning in mild cognitive impairment: A PET activation study , 2007, Brain Research.

[35]  Gunhild Waldemar,et al.  Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.

[36]  Clifford R Jack,et al.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.

[37]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[38]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[39]  Michael Erb,et al.  Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  Biaoyang Lin,et al.  A combined dataset of human cerebrospinal fluid proteins identified by multi‐dimensional chromatography and tandem mass spectrometry , 2007, Proteomics.

[41]  Norman Relkin,et al.  Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.

[42]  Nick C. Fox,et al.  Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD , 2007, Neurobiology of Aging.

[43]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[44]  Anders Wallin,et al.  An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid , 2006, Neuroscience Letters.

[45]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[46]  G. E. Alexander,et al.  Activation of brain regions vulnerable to Alzheimer's disease: The effect of mild cognitive impairment , 2006, Neurobiology of Aging.

[47]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[48]  N. Schuff,et al.  Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI , 2006, Neurology.

[49]  Vince D. Calhoun,et al.  Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis , 2006, The Journal of Neuroscience.

[50]  Kelvin H. Lee,et al.  Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. , 2006, Clinical chemistry.

[51]  Martin Rossor,et al.  Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. , 2006, Archives of neurology.

[52]  Jin-Moo Lee,et al.  Identification of novel brain biomarkers. , 2006, Clinical chemistry.

[53]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[54]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[55]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[56]  Thanh-Thu T. Tran,et al.  Mild cognitive impairment: evaluation with 4-T functional MR imaging. , 2006, Radiology.

[57]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[58]  C. Mariani,et al.  Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[59]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[60]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[61]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[62]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[63]  D. Anchisi,et al.  Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD , 2006, Neurobiology of Aging.

[64]  Clifford R Jack,et al.  Comparisons Between Alzheimer Disease, Frontotemporal Lobar Degeneration, and Normal Aging With Brain Mapping , 2005, Topics in magnetic resonance imaging : TMRI.

[65]  James P. Malone,et al.  Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S , 2005, Molecular & Cellular Proteomics.

[66]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  Hiroshi Matsuda,et al.  The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT , 2005, NeuroImage.

[68]  Katharina Buerger,et al.  Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. , 2005, Combinatorial chemistry & high throughput screening.

[69]  David A Bennett,et al.  High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. , 2005, Clinical chemistry.

[70]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[71]  Brigitte Landeau,et al.  Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study , 2005, NeuroImage.

[72]  M. Albert,et al.  Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.

[73]  J. Jia,et al.  Cerebrospinal fluid tau, Aβ1–42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia , 2005, Neuroscience Letters.

[74]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[75]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[76]  Hilkka Soininen,et al.  CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment , 2005, Neurology.

[77]  R. Buckner,et al.  Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD , 2005, Neurology.

[78]  N. Schuff,et al.  Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. , 2005, Radiology.

[79]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[80]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[81]  S. Leurgans,et al.  MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD , 2004, Neurobiology of Aging.

[82]  K. Nakashima,et al.  Elevated interleukin‐6 levels in cerebrospinal fluid of vascular dementia patients , 2004, Acta neurologica Scandinavica.

[83]  M. Albert,et al.  Medial temporal lobe function and structure in mild cognitive impairment , 2004, Annals of neurology.

[84]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[85]  A. Hofman,et al.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.

[86]  Tetsuya Suhara,et al.  Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. , 2004, Journal of medicinal chemistry.

[87]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[88]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[89]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[90]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[91]  L. Wahlund,et al.  Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[92]  Kaj Blennow,et al.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.

[93]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[94]  J. Barrio,et al.  Molecular-Imaging Probe 2-(1-{6-[(2-Fluoroethyl)(Methyl) Amino]-2-Naphthyl}Ethylidene) Malononitrile Labels Prion Plaques In Vitro , 2003, The Journal of Neuroscience.

[95]  R. Nitsch,et al.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. , 2003, Archives of neurology.

[96]  J. Hodges,et al.  Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment , 2003, Annals of neurology.

[97]  C. Jack,et al.  Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients , 2003, Neurology.

[98]  J. Trojanowski,et al.  Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia , 2003, Neurology.

[99]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[100]  Ove Almkvist,et al.  Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment , 2003, NeuroImage.

[101]  J. Growdon,et al.  Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .

[102]  Eric Achten,et al.  Assessment of Neuroinflammation and Microglial Activation in Alzheimer’s Disease with Radiolabelled PK11195 and Single Photon Emission Computed Tomography , 2003, European Neurology.

[103]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[104]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[105]  I. Zalonis,et al.  CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population , 2003, European journal of neurology.

[106]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[107]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .

[108]  K. Blennow,et al.  Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.

[109]  Kiralee M. Hayashi,et al.  Dynamics of Gray Matter Loss in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[110]  K. Blennow,et al.  Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy , 2003 .

[111]  Philip Scheltens,et al.  Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration , 2003, Neurology.

[112]  S. Wisniewski,et al.  Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment , 2003, Annals of neurology.

[113]  M. Albert,et al.  fMRI studies of associative encoding in young and elderly controls and mild Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[114]  P. Scheltens,et al.  CSF markers related to pathogenetic mechanisms in Alzheimer's disease , 2002, Journal of Neural Transmission.

[115]  A Drzezga,et al.  Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.

[116]  Lars-Olof Wahlund,et al.  Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment , 2002, BMC neurology.

[117]  Tetsuya Mori,et al.  Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease , 2002, Journal of the Neurological Sciences.

[118]  B J Shepstone,et al.  Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. , 2002, Brain : a journal of neurology.

[119]  Katharina Buerger,et al.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.

[120]  Kelvin H. Lee,et al.  Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease , 2002, Electrophoresis.

[121]  J. Morris,et al.  Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type , 2002, Alzheimer disease and associated disorders.

[122]  J. Vente,et al.  Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid , 2002, Neurobiology of Aging.

[123]  G. Evin,et al.  Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides , 2002, Peptides.

[124]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[125]  S. Hirai,et al.  Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group , 2002, Neurobiology of Aging.

[126]  Frederik Barkhof,et al.  Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.

[127]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.

[128]  D. Holtzman,et al.  Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease , 2002, Journal of neurochemistry.

[129]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[130]  H. Arai,et al.  Cerebrospinal Fluid Amyloid β1–42 Levels in the Mild Cognitive Impairment Stage of Alzheimer's Disease , 2001, Experimental Neurology.

[131]  L. Lue,et al.  Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.

[132]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[133]  D. Knopman,et al.  Dissociation of regional activation in mild AD during visual encoding , 2001, Neurology.

[134]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[135]  M. Michalopoulou,et al.  Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[136]  M. Bobinski,et al.  Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[137]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[138]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[139]  Katharina Buerger,et al.  Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.

[140]  G. Frisoni,et al.  Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools , 2001, Journal of neurology, neurosurgery, and psychiatry.

[141]  R. Floris,et al.  Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. , 2001, AJNR. American journal of neuroradiology.

[142]  P. Mehta,et al.  Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.

[143]  R. V. Van Heertum,et al.  SPECT perfusion imaging in the diagnosis of Alzheimer’s disease , 2001, Neurology.

[144]  P. Pietrini,et al.  Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. , 2001, Brain : a journal of neurology.

[145]  S. Rapoport,et al.  Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 , 2001, Annals of neurology.

[146]  O Almkvist,et al.  Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment , 2001, Neuroreport.

[147]  T. Cavalieri,et al.  Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer’s disease , 2001, Brain Research Bulletin.

[148]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[149]  D. Bennett,et al.  Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment , 2001, Annals of neurology.

[150]  K. Jellinger,et al.  Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin‐6 in Alzheimer's disease patients , 2001, Acta neurologica Scandinavica.

[151]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[152]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[153]  T. Montine,et al.  No difference in plasma or urinary F2‐isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls , 2000, Annals of neurology.

[154]  J. Trojanowski,et al.  Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.

[155]  M. Witter,et al.  Functional MR imaging in Alzheimer's disease during memory encoding. , 2000, AJNR. American journal of neuroradiology.

[156]  J. Hoffman,et al.  FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[157]  J. Ashford,et al.  “Preclinical” AD revisited , 2000, Neurology.

[158]  T. Ohnishi,et al.  Longitudinal Evaluation of Early Alzheimer's Disease Using Brain Perfusion Spect the Recruitment Was For , 2000 .

[159]  H. Hampel,et al.  Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients , 2000, Neuroscience Letters.

[160]  A. Suzumura,et al.  Increased Soluble Tumor Necrosis Factor Receptor Levels in the Serum of Elderly People , 2000, Gerontology.

[161]  Á. Hernanz,et al.  Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer’s disease Relationship with IL-6 concentrations , 2000, Brain Research.

[162]  H. Yamanouchi,et al.  Access www.neurology.org now for full-text articles , 2001, Neurology.

[163]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[164]  H. Vanderstichele,et al.  Cerebrospinal beta-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline , 2000, Neuroscience Letters.

[165]  J. Yesavage,et al.  Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF , 2000, Neurology.

[166]  K. Yanagisawa,et al.  Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients , 2000, European Neurology.

[167]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[168]  J. Kornhuber,et al.  Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease , 2000, Neurology.

[169]  T. Yamauchi,et al.  Transthyretin binds amyloid β peptides, Aβ1–42 and Aβ1–40 to form complex in the autopsied human kidney – possible role of transthyretin for Aβ sequestration , 2000, Neuroscience Letters.

[170]  F. Gejyo.  Beta 2-microglobulin amyloid. , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[171]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[172]  B. Winblad,et al.  Levels of α- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients , 2000, Neuroscience Letters.

[173]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[174]  J. Detre,et al.  Assessment of cerebral blood flow in Alzheimer's disease by spin‐labeled magnetic resonance imaging , 2000, Annals of neurology.

[175]  S. Rapoport,et al.  Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls , 1999, Neuroscience Letters.

[176]  P. Vermersch,et al.  Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. , 1999, Neuroreport.

[177]  K. Blennow,et al.  Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.

[178]  E. Bosmans,et al.  Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. , 1999, Journal of psychiatric research.

[179]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[180]  W R Markesbery,et al.  The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. , 1999, The American journal of pathology.

[181]  M. Niculescu,et al.  Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. , 1999, Free radical biology & medicine.

[182]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[183]  K. Blennow,et al.  Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia , 1999, Journal of Clinical Immunology.

[184]  K. Davis,et al.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. , 1999, Archives of neurology.

[185]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[186]  R. D'Hooge,et al.  Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type , 1999, Neurochemistry International.

[187]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[188]  B Engvall,et al.  Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression , 1999, Annals of neurology.

[189]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[190]  K. Davis,et al.  CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease , 1999, Neurology.

[191]  T. Montine,et al.  Increased CSF F2-isoprostane concentration in probable AD , 1999, Neurology.

[192]  G. Landreth,et al.  Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of β-Amyloid and Prion Proteins , 1999, The Journal of Neuroscience.

[193]  M. Rossor,et al.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.

[194]  J. Trojanowski,et al.  Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[195]  A. Kurz,et al.  Tau Protein in Cerebrospinal Fluid Is Significantly Increased at the Earliest Clinical Stage of Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[196]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[197]  H. Arai,et al.  No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia , 1998, Neuroscience Letters.

[198]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[199]  Scott T. Grafton,et al.  Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease. , 1998, Neuropsychology.

[200]  P F Renshaw,et al.  Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. , 1998, AJNR. American journal of neuroradiology.

[201]  T. Montine,et al.  Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.

[202]  P. Mecocci,et al.  Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? , 1998, Alzheimer disease and associated disorders.

[203]  A. Smith,et al.  Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. , 1998, Alzheimer disease and associated disorders.

[204]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[205]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[206]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[207]  Y. Nakamura,et al.  Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. , 1998, Methods and findings in experimental and clinical pharmacology.

[208]  G. Siest,et al.  Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry , 1998, FEBS letters.

[209]  N. Christophidis,et al.  Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease , 1998, Neuroscience Letters.

[210]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[211]  C. Hock,et al.  Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients , 1997, Neuroscience Letters.

[212]  Z. Janka,et al.  Serum interleukin‐6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease , 1997, Acta neurologica Scandinavica.

[213]  J. Trojanowski,et al.  Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease , 1997, Journal of the American Geriatrics Society.

[214]  S. Barger,et al.  Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E , 1997, Nature.

[215]  R. Mrak,et al.  Neuritic plaque evolution in Alzheimer’s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms , 1997, Acta Neuropathologica.

[216]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[217]  H. Möller,et al.  Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease 1 Paper will be presented in part (Abstract) at the Meeting of the Society for Neuroscience, New Orleans, LA, USA in October 1997. 1 , 1997, Neuroscience Letters.

[218]  S. Hirai,et al.  Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease , 1997, Journal of the Neurological Sciences.

[219]  C. Hock,et al.  Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease , 1997, Neuroscience Letters.

[220]  S. Tsuji,et al.  The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43) , 1997, Neurology.

[221]  M. Bobinski,et al.  Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease , 1997, Neurobiology of Aging.

[222]  E. Oguni,et al.  Amyloid β protein in plasma from patients with sporadic Alzheimer's disease , 1996, Journal of the Neurological Sciences.

[223]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[224]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[225]  A. Momose,et al.  Seeing how we hear , 1996, Nature Medicine.

[226]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[227]  Thomas E. Nichols,et al.  Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease , 1996, Neurology.

[228]  K. Jellinger,et al.  Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[229]  P. Southwick,et al.  Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease , 1996 .

[230]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[231]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[232]  N L Foster,et al.  PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[233]  K. Blennow,et al.  A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[234]  B. Winblad,et al.  Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation , 1995, Neuroscience Letters.

[235]  E F Halpern,et al.  Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. , 1995, AJNR. American journal of neuroradiology.

[236]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[237]  J. Trojanowski,et al.  Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.

[238]  Á. Hernanz,et al.  Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[239]  A. Kling,et al.  Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia , 1995, Neurobiology of Aging.

[240]  S. Hirai,et al.  Alpha1-Antichymotrypsin Level in Cerebrospinal Fluid Is Closely Associated with Late Onset Alzheimer's Disease , 1995 .

[241]  L. Chang,et al.  Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. , 1995, Annals of clinical and laboratory science.

[242]  L. Chang,et al.  Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease , 1995, Neurology.

[243]  C. Hock,et al.  Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment , 1995, Annals of neurology.

[244]  S. Hirai,et al.  Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau , 1995, Neuroscience Letters.

[245]  Lars Lannfelt,et al.  Increased cerebrospinal fluid tau in patients with Alzheimer's disease , 1995, Neuroscience Letters.

[246]  T. Hasegawa,et al.  Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia , 1995, Neuroscience Letters.

[247]  E. Wolters,et al.  Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease , 1995, Annals of neurology.

[248]  J. Troncoso,et al.  Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.

[249]  W. Strittmatter,et al.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[250]  H. Wiśniewski,et al.  α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease , 1994, Neurobiology of Aging.

[251]  G. Schellenberg,et al.  Relationship between serum α1-antichymotrypsin and Alzheimer's disease , 1994, Neurobiology of Aging.

[252]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[253]  M. Ball,et al.  Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain Tissue , 1993, Journal of neurochemistry.

[254]  Jan Six,et al.  Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay , 1993 .

[255]  Mark J. West,et al.  Regionally specific loss of neurons in the aging human hippocampus , 1993, Neurobiology of Aging.

[256]  J. Morrison,et al.  Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes , 1993, Neuroscience Letters.

[257]  R. Katzman.,et al.  Serological α1‐Antichymotrypsin in Down's syndrome and Alzheimer's disease , 1992 .

[258]  C. Cotman,et al.  Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[259]  P. Anslow,et al.  Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[260]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[261]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[262]  C. Masters,et al.  Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid , 1991, Neuroscience Letters.

[263]  W. Burke,et al.  Analysis and Quantitation of the β‐Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody‐Based Immunoassay , 1991, Journal of neurochemistry.

[264]  S. Hirai,et al.  α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .

[265]  H. Ghanbari,et al.  Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid. , 1990 .

[266]  R. Mayeux,et al.  Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid , 1990, Neurology.

[267]  D. Leys,et al.  Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease? , 1990, Neurobiology of Aging.

[268]  Y. Takahashi,et al.  Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA. , 1990, Biochemical and biophysical research communications.

[269]  D Wyper,et al.  Measurements of regional cerebral blood flow and cognitive performance in Alzheimer's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[270]  G. Goodwin,et al.  The pattern of function-related regional cerebral blood flow investigated by single photon emission tomography with 99mTc-HMPAO in patients with presenile Alzheimer's disease and Korsakoff's psychosis , 1989, Psychological Medicine.

[271]  F. Tagliavini,et al.  Alzheimer's disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization. , 1989, Biochemical and biophysical research communications.

[272]  Andreas Weidemann,et al.  Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein , 1989, Cell.

[273]  R. Levy,et al.  The investigation of Alzheimer's disease with single photon emission tomography. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[274]  P Gerundini,et al.  Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[275]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[276]  B. Frangione,et al.  Beta-2 microglobulin is an amyloidogenic protein in man. , 1985, The Journal of clinical investigation.

[277]  K. Jellinger,et al.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients , 2009, Journal of Neural Transmission.

[278]  S. Younkin,et al.  Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. , 2008, Neurology.

[279]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[280]  A. Verma,et al.  Imaging of Amyloid Burden and Distribution in Cerebral Amyloid Angiopathy , 2008 .

[281]  M. Mann,et al.  Integrated analysis of the cerebrospinal fluid peptidome and proteome. , 2008, Journal of proteome research.

[282]  T. J. Grabowski,et al.  Proteome-based plasma biomarkers for Alzheimer's disease , 2007 .

[283]  Hilkka Soininen,et al.  CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. , 2007, Neurobiology of aging.

[284]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[285]  B. Hyman,et al.  Plasma Abeta levels do not reflect brain Abeta levels. , 2007, Journal of neuropathology and experimental neurology.

[286]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[287]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[288]  Tomasz Sobow,et al.  Biochemical markers and risk factors of Alzheimer's disease. , 2005, Current Alzheimer research.

[289]  R. Aebersold,et al.  Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[290]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[291]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[292]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[293]  T. Montine,et al.  Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[294]  P. Lewczuk,et al.  Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. , 2004, Neurobiology of aging.

[295]  K. Blennow,et al.  Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. , 2003, Movement disorders : official journal of the Movement Disorder Society.

[296]  J. Growdon,et al.  Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.

[297]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.

[298]  K. Blennow,et al.  Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. , 2002, Dementia and Geriatric Cognitive Disorders.

[299]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[300]  T. Montine,et al.  Cerebrospinal Fluid Aβ42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls , 2001 .

[301]  T. Montine,et al.  Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. , 2001, Archives of pathology & laboratory medicine.

[302]  B. Winblad,et al.  Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. , 2000, Neuroscience Letters.

[303]  K. Blennow,et al.  CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.

[304]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[305]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[306]  J. Kornhuber,et al.  Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. , 2000, Neurology.

[307]  P. S. St George-Hyslop,et al.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.

[308]  T. Yamauchi,et al.  Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney - possible role of transthyretin for abeta sequestration. , 2000, Neuroscience letters.

[309]  S A Small,et al.  Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.

[310]  R. D'Hooge,et al.  Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. , 1999, Neurochemistry international.

[311]  S. Hirai,et al.  Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. , 1998, Journal of the neurological sciences.

[312]  P. Southwick,et al.  Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. , 1996, Journal of neurochemistry.

[313]  E. Oguni,et al.  Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. , 1996, Journal of the neurological sciences.

[314]  D. Goldgaber,et al.  Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. , 1996, Ciba Foundation symposium.

[315]  P Riederer,et al.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.

[316]  S. Hirai,et al.  Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. , 1995, Internal medicine.

[317]  A. Kling,et al.  Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. , 1995, Neurobiology of aging.

[318]  L Carlin,et al.  Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. , 1995, Archives of neurology.

[319]  G. Schellenberg,et al.  Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease. , 1994, Neurobiology of aging.

[320]  H. Wiśniewski,et al.  Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. , 1994, Neurobiology of aging.

[321]  L. Hansen,et al.  Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease. , 1992, Annals of neurology.

[322]  S. Hirai,et al.  Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain. , 1991, The American journal of pathology.

[323]  S. Hirai,et al.  Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. , 1990, Annals of neurology.

[324]  R. Mayeux,et al.  Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. , 1990, Neurology.

[325]  H. Petit,et al.  [Alzheimer's disease: study by single photon emission tomography (Hm PAO Tc99m)]. , 1989, Revue neurologique.

[326]  M. Steinling,et al.  Maladie d'Alzheimer. Etude par tomographie d'émission monophotonique (Hm PAO Tc99m) , 1989 .

[327]  Mary Ann Moran,et al.  Synthesis and Evaluation , 1986 .